EMD 57439

Drug Profile

EMD 57439

Latest Information Update: 17 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck KGaA
  • Developer Merck KGaA; Nonindustrial source; Roche Palo Alto LLC
  • Class Cardiotonics; Small molecules
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Heart failure

Most Recent Events

  • 09 Nov 1999 Preclinical development for Congestive heart failure in Japan (Unknown route)
  • 09 Nov 1999 A preclinical study has been added to the Heart Failure pharmacodynamics section
  • 12 Aug 1998 No-Development-Reported for Heart failure in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top